Treatment of vaginal atrophy with ultra-low-dose 10 MCG estradiol vaginal tablets

US Obstetrics and Gynecology

Volumn 6, Issue 1, 2011, Pages 47-50

  Maamari, Ricardo V ^a  

^a NOVO NORDISK INC   (United States)

Author keywords

Absorption; Estrogen; Hormonal; Menopause; Vaginal atrophy

Indexed keywords

EID: 84860340886     PISSN: 17546168     EISSN: 17546176     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rossin-Amar B, Vaginal dryness in the menopausal woman (physiological and psychological aspects), Gynecol Obstet Fertil, 2000;28:245-9
2. Archer DF, Efficacy and tolerability of local estrogen therapy for urogenital atrophy, Menopause, 2010;17:194-203
3. Bachmann GA, Nevadunsky NS, Diagnosis and treatment of atrophic vaginitis, Am Fam Physician, 2000;61:3090-6
4. Beard MK, Atrophic vaginitis. Can it be prevented as well as treated?, Postgrad Med, 1992;91:257-60.
5. Pandit L, Ouslander JG, Postmenopausal vaginal atrophy and atrophic vaginitis, Am J Med Sci, 1997;314:228-31
6. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation, Washington, DC: US Department of Health and Human Services, 2003
7. Ulrich LS, Naessen T, Elia D, et al., Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy, Climacteric, 2010;13:228-37.
8. Sturdee DW, Panay N, Recommendations for the management of postmenopausal vaginal atrophy, Climacteric, 2010;13:509-22
9. Labrie F, Intravaginal DHEA, by a strictly local action, exerts beneficial effects on both vaginal atrophy symptoms and sexual dysfunction, Horm Mol Biol Clin Investig, 2010;4(1):499-507
10. Utain WH, Bahmann GA, Cahill EB, et al., Estrogen and progestin use in postmenopausal women: 2010 position statement of The North American Menopause Society, Menopause, 2010;17:242-55.
11. Gompel A, Rozenberg S, Barlow DH, The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy, Maturitas, 2008;61:227-32
12. Pines A, Sturdee DW, Birkhauser MH, et al., IMS updated recommendations on postmenopausal hormone therapy, Climacteric, 2007;10:181-94.
13. Seifert-Klauss V, Kingwell E, Hitchcock CL, et al., Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society, Menopause, 2008;15:203-4.
14. Simon J, Nachtigall L, Gut R, et al., Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet, Obstet Gynecol, 2008;112:1053-60.
15. Committee for Medical Products for Human Use (CHMP), Guideline on clinical investigation of medicinal products for hormone replacement therapy of estrogen deficiency symptoms in postmenopausal women, London: European Medicines Agency, 2005
16. Furness S, Roberts H, Marjoribanks J, et al., Hormone therapy in postmenopausal women and risk of endometrial hyperplasia, Cochrane Database Syst Rev, 2009;CD000402.
17. Green PK, Weiss NS, McKnight B, et al., Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States), Cancer Causes Control, 1996;7:575-80.
18. Sturdee DW, Endometrial Cancer and HRT, Reviews in Gynaecological Practice, 2005;5:51-6
19. Simon J, Nachtigall L, Ulrich LG, et al., Endometrial safety of ultra-low-dose estradiol vaginal tablets, Obstet Gynecol, 2010;116:876-83.
20. Eugster-Hausmann M, Waitzinger J, Lehnick D, Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets, Climacteric, 2010;13:219-27
21. Santen RJ, Demers L, Ohorodnik S, et al., Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy, Steroids, 2007;72:666-71.
22. Stanczyk FZ, Lee JS, Santen RJ, Standardization of steroid hormone assays: why, how, and when?, Cancer Epidemiol Biomarkers Prev, 2007;16:1713-9
23. Nilsson K, Heimer G, Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinetic and pharmacodynamic study, Maturitas, 1992;15:121-7